b
r
c
vizier
acronym
research
project
entitl
compar
structur
genom
viral
enzym
involv
replic
fund
european
commiss
novemb
april
involv
partner
countri
paper
describ
organ
project
cultur
creat
multidisciplinari
essenc
discuss
main
themat
section
project
strategi
adopt
optim
integr
variou
scientif
field
common
object
obtain
crystal
structur
widest
varieti
rna
viru
replic
enzym
document
valid
potenti
drug
target
discuss
themat
section
overal
organ
success
bottleneck
around
protein
product
pipelin
low
hang
fruit
strategi
measur
direct
problem
solv
discuss
possibl
futur
option
largescal
project
area
antivir
drug
design
seri
accompani
paper
antivir
research
project
achiev
present
viru
famili
vizier
project
launch
octob
end
april
vizier
approxim
acronym
viral
enzym
involv
replic
first
largescal
multicountri
coordin
research
initi
address
challeng
concept
familiesgenu
regard
mainli
viral
genom
structur
biolog
use
drug
design
special
emphasi
achiev
within
vizier
project
alphavirus
coronavirus
hilgenfeld
et
al
issu
flavivirus
picornavirus
norder
et
al
issu
calicivirus
rohayem
et
al
issu
arenavirus
bunyavirus
charrel
et
al
issu
rhabdovirus
assenberg
et
al
issu
chapter
ommiss
reflect
either
deliber
choic
start
project
eg
hepat
c
viru
orthomyxovirus
vizier
symposium
write
stage
ommit
virus
although
interest
sometim
truli
origin
result
obtain
within
vizier
amount
acquir
data
justifi
full
chapter
eg
reovirus
astrovirus
paramyxovirus
addit
method
chapter
includ
symposium
inde
special
bioinformat
crystallograph
method
develop
satisfi
vizier
special
need
believ
method
tool
difficult
publish
context
vizier
symposium
sure
deserv
special
mention
might
use
grow
structur
virolog
commun
initi
core
activ
vizier
largescal
viral
structur
genom
project
sgp
meant
address
problem
small
number
viral
protein
structur
known
atom
resolut
requir
antivir
drug
design
sg
part
per
se
protein
product
crystal
structur
determin
repres
overal
ec
contribut
cours
project
origin
concept
expand
present
form
rest
mainli
three
scientif
field
strong
viral
genom
compon
ii
origin
structur
genom
core
iii
integr
drug
candid
discoveri
activ
includ
chemist
loop
back
basic
virolog
lab
mechanist
proofofconcept
studi
replic
enzym
chosen
primari
target
first
essenti
viru
lifecycl
inhibit
lead
effect
viru
growth
suppress
second
due
structur
mechanist
conserv
across
viral
famili
replic
enzym
less
prone
variat
structur
protein
theori
facilit
subsequ
select
broadspectrum
antivir
molecul
well
minimis
emerg
drug
resist
third
viral
replic
enzym
often
uniqu
diverg
enough
host
enzym
expect
decent
drug
select
minim
potenti
toxic
due
crossinhibit
host
enzym
enzym
thu
constitut
socal
valid
target
drug
discoveri
design
field
structurebas
antivir
drug
design
era
definit
open
advent
antihiv
proteas
drug
reach
market
review
see
mastrolorenzo
et
al
hand
also
increas
number
enzym
function
infer
examin
crystal
structur
provid
new
opportun
ration
antivir
drug
design
context
vizier
took
posit
increas
connect
virologyantivir
field
structur
genom
commenc
vizier
program
alreadi
thought
structur
genom
could
contribut
protein
function
assign
zarembinski
et
al
mani
largescal
sgp
launch
target
full
proteom
subset
target
differ
genom
first
focus
archaebacteria
methanobacterium
thermoautotrophicum
christendat
et
al
follow
initi
driven
larg
consortia
europ
spine
http
wwwspineuropeorg
japan
riken
http
wwwrsgirikengojp
usa
psi
http
kbpsistructuralgenomicsorg
transatlant
sgc
http
wwwsgcutorontoca
main
common
object
gener
structur
data
relat
human
health
systemat
panspeci
approach
one
genom
time
enough
keep
larg
consortium
busi
vizier
approach
uniqu
structur
biolog
inde
main
object
vizier
provid
structur
data
potenti
new
drug
target
also
unlik
consortia
vizier
focus
limit
rang
protein
involv
viral
replic
allegedli
bore
antivir
target
potenti
exist
consortia
reli
low
hang
fruit
approach
express
mean
easi
target
ie
protein
proceed
without
major
difficulti
structur
analysi
address
first
respect
vizier
introduc
new
variat
mean
express
exampl
two
protein
enzym
central
replic
consid
flaviviru
genu
consequ
major
goal
obtain
least
one
crystal
structur
flaviviru
subdomain
term
low
hang
fruit
would
refer
first
determin
would
turn
help
solv
mani
relat
possibl
along
flavivir
phylogenet
tree
low
hang
target
therefor
consid
templat
acceler
structur
determin
insid
viral
genu
insid
class
enzym
approach
initi
met
sceptic
amongst
vizier
crystallograph
commun
despit
frank
enthusiasm
virolog
commun
inde
first
crystal
structur
known
structur
homologu
usual
excit
origin
unknown
protein
bear
potenti
reveal
novel
fold
nevertheless
panvir
approach
made
possibl
hit
sever
bird
one
stone
inde
viral
genom
smallsiz
compar
eukaryot
genom
panvir
approach
must
elig
structur
genom
denomin
fund
first
back
concept
anticip
emerg
virus
see
second
made
possibl
tri
produc
crystal
protein
differ
isol
enhanc
chanc
success
posteriori
structur
data
complement
largescal
sequenc
viral
genom
within
viral
famili
may
help
address
inevit
question
polymorph
drug
susceptibilityresist
alreadi
occur
influenza
neuramidas
hiv
enzym
panvir
approach
develop
vizier
immedi
consequ
crystal
structur
determin
viru
famili
new
viru
emerg
replic
enzym
resembl
someth
alreadi
character
structur
level
might
alreadi
initi
drug
candid
fact
concept
exemplifi
coronaviru
research
sar
crisi
hilgenfeld
group
univers
germani
collabor
determin
tgev
main
proteinas
structur
first
coronaviru
protein
crystal
structur
anand
et
al
structur
virolog
field
young
coronavirus
line
rna
virus
interestingli
structur
biolog
work
provid
exampl
scientif
anticip
direct
toward
get
necessari
scientif
knowledg
design
drug
emerg
rna
virus
inde
tgev
proteas
inhibitor
could
suggest
base
chloromethylketon
pharmacophor
due
activ
site
similar
found
rhinoviru
sarscov
emerg
nucleotid
sequenc
new
coronaviru
made
avail
internet
shortli
viru
isol
identif
marra
et
al
took
day
dr
hilgenfeld
figur
sar
proteas
close
relat
tgev
propos
structur
model
tgev
inhibitor
backbon
could
serv
potent
start
point
antisarscov
drug
design
six
month
later
structur
sarscov
main
proteas
structur
solv
vizier
project
chikungunya
outbreak
provid
anoth
unexpect
opportun
acceler
acquisit
knowledg
poorli
character
viru
famili
viral
macrodomain
constitut
interest
exampl
macrodomain
protein
domain
found
coronavirida
togavirida
rubella
viru
hepat
e
viru
macrodomain
coronavirus
subject
sever
structur
studi
within
outsid
vizier
egloff
et
al
saikatendu
et
al
translat
accumul
knowledg
togavirida
famili
undoubtedli
acceler
crystal
structur
determin
sever
alphaviru
macrodomain
includ
chikungunya
viru
crystal
structur
determin
anticip
concept
commun
repeatedli
vizier
consortium
scientif
meet
interact
lay
press
permeat
scientif
commun
perhap
extent
also
gener
public
certainli
also
stir
debat
drug
design
industri
would
abl
stay
clear
global
problem
emerg
virus
anticip
feasibl
market
evalu
sine
qua
non
condit
drug
develop
viral
nonstructur
protein
usual
larg
polyprotein
compris
sever
enzym
activ
function
singl
polypeptid
chain
either
later
proteolyt
process
possibl
reason
protein
crystal
lie
difficulti
express
solubl
form
suitabl
crystal
draw
flavivir
domain
design
choi
et
al
malet
et
al
decid
systemat
modular
approach
coupl
vizier
special
bioinformat
domain
predict
virolog
protein
factori
sens
vizier
forefront
applic
high
throughput
htp
techniqu
viru
research
techniqu
classic
present
laboratori
perform
antivir
screen
academ
virolog
lab
overal
process
drug
discoverydesign
clear
tendenc
integr
requir
scientif
field
much
possibl
vizier
defin
start
point
easi
need
viral
genom
postgenom
identifi
earli
describ
howev
one
difficulti
defin
vizier
stop
drug
discoverydesign
process
leav
drug
develop
special
develop
one
obviou
endlin
unpredict
natur
medicin
chemistri
involv
hittolead
develop
discov
hit
structurebas
chemistri
implement
would
requir
special
chemist
seem
appropri
subcontract
secondari
chemistri
rather
tri
integr
field
medicin
chemistri
vizier
program
therefor
vizier
aim
provid
structur
data
drug
design
option
hit
begin
feed
drug
discoveri
pipelin
pipelin
organis
center
core
laboratori
genom
medicin
chemistri
effort
integr
connect
activ
describ
vizier
reli
pipelin
bioinformat
medicin
chemistri
principl
pipelin
organis
sever
advantag
first
document
effort
easi
simpl
provid
appropri
laboratori
inform
manag
system
lim
duplic
effort
avoid
optim
flow
feedback
inform
facilit
well
share
protocol
technic
improv
databas
server
howev
central
pipelin
bear
obviou
limit
sequenti
organis
depend
singl
bottleneck
appear
somewher
pipelin
downstream
activ
group
risk
affect
ideal
pipelin
run
appropri
steadyst
irrig
variou
activ
preexist
time
zero
project
unpredict
difficulti
expectedli
arisen
jeopard
workflow
difficulti
actual
promot
organis
special
workgroup
focus
target
interest
structur
andor
antivir
design
point
view
interest
evalu
result
accord
activ
field
viru
famili
see
certainli
orient
futur
project
achiev
long
term
facilit
design
molecular
structurebas
strategi
inhibit
replic
broad
rang
clinic
relev
virus
word
success
failur
directli
benefit
global
public
health
bioinformat
section
propos
primer
sequenc
deriv
viral
sequenc
use
virusinfect
cell
use
rtpcr
primer
gener
cdna
target
sequenc
sequenc
fig
deriv
either
exist
sequenc
thu
section
work
start
project
start
novel
sequenc
deriv
genom
section
fig
show
actual
predict
made
exceed
object
predict
object
low
fact
predictor
tool
refin
develop
project
gorbalenya
et
al
issu
two
toolbas
develop
implement
vizier
vazymolo
virali
deliv
hundr
predict
either
selfserv
basi
vazymolo
request
expert
curat
virali
version
vazymolo
exist
vizier
ferron
et
al
consider
expand
implement
project
free
access
virali
databas
also
fulli
oper
approxim
year
project
allow
cruis
speed
target
predict
compat
vizier
object
number
specif
bioinformat
tool
techniqu
significantli
contribut
crystal
viral
enzym
domain
perhap
one
import
identif
elimin
uncrystalliz
materi
earli
step
domain
definit
thu
first
virtu
avoid
interor
connect
domain
bring
flexibl
target
solut
imped
crystal
also
observ
express
level
multidomain
protein
algebra
sum
separ
domain
express
level
exampl
ntermin
ctermin
domain
flaviviru
express
separ
high
level
compar
express
fulllength
protein
consider
decreas
reason
may
multipl
eg
protein
degrad
andor
cleavag
gene
express
care
et
al
relat
flexibl
fulllength
protein
avail
proven
less
amen
crystal
despit
intens
effort
sever
lab
among
uniqu
structur
obtain
use
singl
predict
construct
wherea
other
multi
fig
statu
viral
target
vizier
product
pipelin
step
repres
advanc
target
form
silico
sequenc
submit
cdna
deriv
viral
rna
pcr
clone
recombin
protein
express
solubl
form
solubl
purifi
submit
crystallogenesi
xtal
screen
whose
crystal
structur
determin
structur
uniqu
structur
refer
crystal
structur
singl
protein
either
complex
unligand
blue
stack
repres
actual
achiev
compar
object
project
red
stack
interpret
refer
color
citat
figur
reader
refer
web
version
articl
construct
strategi
see
section
requir
improv
either
solubl
crystallogenesi
interestingli
amongst
lowest
hang
fruit
target
flaviviru
methyltransferas
homologu
crystal
either
larg
short
form
unpredict
result
point
limit
ration
sequencebas
design
thu
coupl
method
empir
multiboundari
construct
design
partli
explain
increas
number
domain
submit
databas
likewis
effort
made
toward
pure
random
approach
select
solubl
domain
larg
target
gene
refractori
solubl
express
variou
domain
predict
cornvik
et
al
although
valid
select
solubl
fragment
membran
protein
manolaridi
et
al
method
provid
new
domain
boundari
miss
use
bioinformat
predict
among
structur
determin
use
singl
construct
rna
virus
convers
solubl
stabl
domain
obtain
rna
virus
result
experiment
design
use
extens
multiconstruct
limit
proteolysi
unstabl
protein
ssrna
viral
rdrp
bioinformat
useless
provid
boundari
could
suggest
region
modul
might
found
three
reason
could
explain
differ
ssrna
virus
first
sever
structur
modul
ssrna
viru
alreadi
avail
protein
data
bank
pdb
render
domain
design
easi
wherea
structur
data
avail
ssrna
viral
replicas
second
ssrna
viral
nonstructur
protein
process
proteas
suggest
small
modul
could
behav
independ
other
ssrna
viru
nonstructur
protein
nsp
proteolysi
occur
differ
domain
may
need
interact
may
unstabl
produc
alon
nevertheless
success
regard
influenza
rdrp
subunit
use
random
strategi
seem
invalid
hypothesi
dia
et
al
guilligay
et
al
third
correctli
design
modul
may
fail
express
step
reason
relat
express
host
protein
vizier
consortium
gather
wealth
partial
complet
genom
sequenc
data
larg
number
rna
virus
rna
viru
genom
project
panel
virus
made
avail
within
consortium
addit
larg
number
isol
clinic
interest
obtain
character
hot
virus
dengu
viru
isol
chikungunya
viru
isol
rsv
isol
human
enterovirus
isol
influenza
virus
isol
reservoir
strain
clinic
relev
import
futur
studi
rel
littl
mostli
fragmentari
inform
rna
viral
genom
avail
start
vizier
complet
genom
sequenc
inform
essenti
obtain
comprehens
pictur
genom
organis
rna
virus
genet
divers
variabl
howev
ultim
goal
achiev
viru
famili
flavivirus
tickborn
flavivirus
aedesborn
flavivirus
culexborn
flavivirus
flavivirus
known
vector
ie
virus
sequenc
addit
new
virus
infect
mosquito
insectivirus
identifi
new
speci
complet
sequenc
x
de
lamballeri
unpublish
complet
genu
character
reach
arenavirus
complet
sequenc
analysi
speci
produc
phylogeni
recent
review
addit
viru
discoveri
genom
yield
character
differ
arenaviru
lcmv
isol
tabl
advanc
statu
cdna
construct
name
short
long
correspond
nterminu
arenaviru
l
gene
cdna
amplifi
distinct
arenavirus
left
column
step
along
protein
product
pipelin
indic
clone
crystal
structur
determin
use
xray
crystallographi
statu
target
along
pipelin
color
code
step
green
mean
step
success
red
fail
alphavirus
complet
sequenc
chikungunya
viru
indian
ocean
gabon
itali
madagascar
filovirus
ebola
viru
strain
cirmf
world
import
collect
character
multigen
sequenc
collabor
dr
leroy
irdgabon
appar
viral
genom
activ
slow
begin
project
later
gener
materi
pipelin
abl
handl
practic
point
view
clone
express
gene
mani
unexpect
mutat
polymorph
reduc
enthusiasm
motiv
scientist
aim
publish
result
scientif
paper
notori
limit
work
loos
character
viral
isol
subject
mani
passag
cell
cultur
genom
strategi
includ
need
sequenc
close
relat
strain
virus
decis
total
vindic
observ
close
relat
strain
viru
show
differ
characterist
challeng
potenti
inhibitor
enzym
activ
observ
also
led
conclus
futur
work
requir
greater
emphasi
field
isol
virus
avoid
risk
design
antivir
target
laboratori
strain
thu
sinc
virus
amongst
genet
variabl
organ
recognis
need
studi
authent
field
isol
whenev
possibl
genom
strategi
also
emphasis
fact
previzi
viral
world
present
databas
whole
genom
nucleic
acid
sequenc
wholli
inadequ
major
beneficiari
extens
genom
studi
crystallograph
abl
demonstr
higher
averag
success
rate
solv
crystal
structur
replic
enzym
domain
wide
rang
rna
virus
inde
might
well
one
protein
resist
express
crystal
could
express
crystal
close
relat
isol
case
first
crystal
structur
unknown
viral
famili
invari
repres
breakthrough
later
relat
crystal
structur
greatli
facilit
molecular
replac
techniqu
make
use
first
atom
coordin
one
may
think
term
visibl
impact
subsequ
crystal
structur
less
interest
crystallograph
found
mani
instanc
howev
origin
structur
determin
could
come
variou
subsequ
target
expand
interest
beyond
firstev
structur
determin
given
viru
famili
tabl
virologist
epidemiologist
point
tabl
comparison
success
rate
target
address
sever
structur
genom
project
report
target
db
versu
vizier
success
rate
indic
step
along
protein
product
pipelin
crystal
structur
determin
view
structur
potenti
interest
long
cover
phylogenet
space
describ
emerg
viru
unexpect
demand
virologist
wish
includ
loop
interest
drug
candid
found
last
stage
vizier
pipelin
logic
demand
found
two
main
justif
afterward
virolog
lab
amongst
best
qualifi
partner
assess
drug
suscept
spectra
largest
viru
collect
definit
help
cement
vizier
commun
make
peopl
differ
background
meet
work
togeth
fig
show
target
amplif
yield
cdna
rtpcr
propos
sequenc
fact
target
account
differ
either
address
address
sever
express
system
initi
chosen
possibl
express
system
viral
protein
aim
cdna
clone
set
express
vector
use
ligationindepend
clone
method
walhout
et
al
aslanidi
de
jong
librari
made
clone
cdna
built
project
lead
larg
divers
well
document
resourc
viral
domain
involv
replic
clone
rather
effici
step
clone
obtain
repres
success
rate
due
robust
ligationindepend
procedur
commerci
avail
respect
largescal
clone
campaign
minim
handl
freezethaw
sensit
reagent
perhap
contribut
rather
straightforward
success
step
noteworthi
clone
success
evalu
upon
sequenc
bona
fide
cdna
insert
clone
consid
failur
less
case
failur
assess
absenc
recombin
coloni
presenc
incorrect
cdna
insert
unexpect
stop
codon
frameshift
delet
gener
rtpcr
pcr
step
first
year
express
system
evalu
e
coli
proven
effici
clone
host
thu
decid
stop
explor
express
method
use
nonbacteri
express
system
order
reinforc
product
pipelin
base
express
e
coli
berrow
et
al
care
et
al
prokaryot
system
becam
major
protein
crystal
provid
one
structur
determin
result
protein
produc
insect
cell
two
kind
strategi
success
use
sinc
rna
viru
enzym
deriv
polyprotein
precursor
vizier
strategi
mainli
reli
ration
domain
modul
design
see
section
detail
howev
mani
case
choic
start
andor
stop
codon
modul
obviou
sever
gene
boundari
must
chosen
trialanderror
procedur
combin
multipl
start
stop
lead
clone
construct
differ
length
given
domain
far
crystal
concern
approach
name
multiconstruct
strategi
demonstr
twice
success
work
finetun
solubl
express
singl
construct
graslund
et
al
use
vizier
either
solubl
protein
reluct
crystal
poor
diffract
data
obtain
given
domain
one
first
success
use
strategi
vizier
determin
crystal
structur
west
nile
viru
rdrp
use
gene
construct
amongst
two
led
diffract
crystal
anoth
exampl
provid
speroni
et
al
illustr
need
screen
put
boundari
domain
regard
solubl
crystal
strategi
also
limit
particular
negativestrand
rna
virus
inde
domain
design
base
l
protein
rhabdovirus
none
produc
crystal
iter
addit
delet
amino
acid
sequenc
may
also
help
protein
solubl
case
echoviru
domain
addit
amino
acid
increment
allow
select
construct
express
solubl
protein
amongst
latter
one
purifi
success
lead
determin
low
resolut
structur
hexam
form
papageorgi
et
al
submit
also
took
advantag
biolog
divers
avail
cdna
librari
overcom
failur
protein
express
solubl
crystal
test
sever
homologu
expect
least
one
would
lead
solubl
protein
crystal
strategi
initi
assess
flaviviru
nonstructur
protein
exampl
amongst
differ
helicas
produc
purifi
methyltransferas
purifi
rdrp
produc
crystal
trial
difficult
target
eg
negativestrand
rna
virus
use
larg
panel
homologu
also
help
provid
domain
suitabl
crystal
exampl
differ
construct
arenaviru
domain
clone
express
lead
purif
two
success
rate
highlight
import
take
advantag
sequenc
divers
see
tabl
particularli
interest
note
parana
viru
protein
domain
led
crystal
whose
maximum
resolut
could
lower
coupl
multiconstruct
multihomologu
strategi
overcam
difficulti
lcmv
protein
provid
crystal
diffract
fig
show
signific
bottleneck
remain
express
solubl
protein
domain
success
rate
step
wherea
expect
mainli
establish
examin
spine
european
project
preced
vizier
statist
data
provid
targetdb
http
targetdbpdborg
see
tabl
next
stepprotein
purif
use
parallel
semiautom
approach
sinc
protein
purif
uniqu
virtual
need
individu
care
dedic
research
stage
protein
purifi
homogen
protein
platform
other
transfer
crystallographi
lab
repeatedli
prepar
protein
batch
crystallogenesi
experi
gap
observ
protein
remain
unpurifi
line
data
provid
sg
consortia
see
tabl
purifi
protein
go
crystal
trial
howev
fig
show
protein
crystal
trial
yield
uniqu
structur
later
expand
structur
protein
proteinligand
ie
averag
two
crystal
structur
per
uniqu
target
tabl
although
agreement
standard
result
sg
initi
see
tabl
drastic
reduct
success
crystal
trial
attempt
yield
crystal
structur
appar
repres
achil
heel
structur
genom
terwillig
et
al
howev
mani
observ
may
temper
attenu
appar
failur
crystal
structur
first
protein
kind
viru
famili
determin
interest
tend
drop
among
crystallograph
commun
mention
therefor
sever
crystal
type
protein
eg
picornaviru
polymeras
flaviviru
mtase
etc
may
well
remain
unattend
forev
solut
judg
worth
challeng
nevertheless
qualiti
diffract
remain
signific
problem
even
though
crystal
drop
setup
autom
whole
optim
process
laborintens
requir
full
attent
dedic
investig
classic
structur
biolog
project
interestingli
difficult
problem
solv
dedic
scientist
highli
special
softwar
crystal
structur
determin
well
crystal
structur
determin
challeng
target
case
west
nile
rdrp
rdrp
coxsacki
viru
complex
gruez
et
al
larg
proport
amino
acid
illdefin
structur
model
arenaviru
protein
domain
whose
phase
could
easili
found
coronaviru
sud
domain
tan
et
al
avail
dedic
softwar
whose
improv
beta
version
made
avail
prior
dissemin
structur
biolog
commun
sure
help
solv
improv
structur
model
gener
vizier
addit
varieti
tool
develop
help
analysi
structur
model
gener
project
gorbalenya
et
al
issu
positivestrand
rna
virus
especi
flavivirus
nidoviral
provid
largest
number
structur
replic
complex
shown
tabl
flavivirus
project
contribut
structur
determin
four
function
domain
replic
machineri
ie
proteas
ntpasehelicas
methyltransferas
rna
depend
rna
polymeras
well
provid
addit
data
regard
organ
replic
complex
new
fold
origin
structur
expect
flaviviru
subproject
target
essenti
viral
replic
thu
good
candid
antivir
discoveri
detail
follow
review
sampath
padmanabhan
chappel
et
al
dong
et
al
malet
et
al
new
structur
may
thu
direct
impact
antivir
discoveri
field
methyltransferas
address
domain
structur
result
structur
provid
model
omethyl
well
methyl
ii
overview
structur
diverg
along
flaviriru
phylogenet
tree
least
one
structur
one
repres
three
branch
mosquitoborn
tickborn
virus
known
vector
determin
structurebas
drug
discoveri
complement
experiment
valid
alreadi
initi
yield
select
compound
micromolar
rang
structur
two
first
flaviviru
rdrp
west
nile
dengu
viru
also
determin
within
vizier
project
provid
valuabl
new
inform
drug
discoveri
near
futur
contrast
flavivirus
number
divers
nonstructur
protein
subdomain
much
import
famili
nidoviral
among
structur
determin
structur
obtain
within
vizier
nevertheless
product
solubl
protein
enabl
function
biochem
studi
decroli
et
al
nedialkova
et
al
one
strike
observ
could
made
structur
result
concern
macrodomain
begin
project
crystal
structur
sar
macrodomain
alreadi
avail
egloff
et
al
moreov
macrodomain
thought
dispens
viral
replic
putic
et
al
may
good
candid
antivir
discoverydesign
could
thu
question
focu
domain
product
structur
determin
even
though
domain
belong
low
hang
fruit
categori
actual
structur
function
studi
macrodomain
show
signific
structur
differ
substrat
affin
select
amongst
coronavirus
tan
et
al
piotrowski
et
al
invest
effort
coronaviru
macrodomain
design
product
help
alphaviru
macrodomain
definit
crystal
although
mani
structur
avail
macrodomain
role
remain
elus
certainli
much
easier
tackl
function
assess
use
revers
genet
alphaviru
genu
coronaviru
inde
infecti
clone
subgenom
replicon
less
laborintens
former
latter
genu
exampl
illustr
possibl
benefit
panviru
analysi
rather
reli
uniqu
viru
model
among
structur
determin
positivesens
singlestrand
rna
virus
except
one
proteas
rdrp
picornavirida
calicivirida
except
structur
work
associ
enzymat
work
complement
order
unravel
first
crystal
structur
viral
famili
astrovirida
first
demonstr
proteas
activ
case
structur
activ
viral
famili
clearli
lag
behind
studi
virus
indic
one
vizier
concept
stay
awar
rna
viru
may
emerg
near
futur
respect
although
astrovirida
work
perform
vizier
could
justifi
full
chapter
issu
human
pathogen
astroviru
serin
proteas
crystal
structur
determin
resolut
may
one
day
speed
drug
design
case
rdrp
exampl
detail
initi
rna
synthesi
quit
divers
rna
viru
world
initi
may
primerindepend
eg
flavivirus
primerdepend
eg
arenavirus
proteinprim
eg
picornavirus
unknown
eg
coronavirus
sever
exampl
vizier
unexpect
result
may
relev
drug
design
exampl
coxsacki
viru
rdrp
structur
determin
complex
vpg
gruez
et
al
found
form
complex
differ
footandmouth
viru
rdrpvpg
complex
ferrerorta
et
al
also
caliciviru
rdrp
polymeras
structur
suggest
enzym
experi
show
calicivirus
initi
rna
synthesi
primerindepend
independ
manner
fullerton
et
al
three
crystal
structur
determin
ds
rna
virus
among
two
directli
involv
viru
replic
one
rdrp
one
cap
enzym
sutton
et
al
crystal
structur
determin
l
protein
domain
involv
replic
ss
rna
virus
probabl
challeng
object
project
sinc
structur
avail
start
project
sever
hundr
l
protein
construct
larg
divers
viru
collect
express
e
coli
insect
cell
contribut
lower
pipelin
statist
five
crystal
structur
determin
amongst
two
domain
l
protein
first
one
ntermin
part
lcmv
refer
ss
rna
viru
segment
genom
tabl
structur
data
yet
relat
domain
known
fold
pdb
provid
evid
regard
function
nevertheless
revers
genet
avail
arenavirus
review
de
la
torr
could
rapidli
indic
domain
carri
essenti
viral
function
well
relev
target
structurebas
drug
design
arenavirus
section
function
enzym
activ
test
either
basi
silico
predict
gener
predict
avail
establish
one
lab
biochem
enzym
test
made
avail
partnership
vizier
websit
inde
number
gener
biochem
test
give
interest
result
aim
discoveri
novel
function
rna
bind
specif
nucleotid
bind
rnacap
bind
cofactor
bind
exampl
arenavirus
domain
describ
specif
gtp
bind
would
point
rnacap
snatch
enzym
rna
synthesi
prime
sinc
extra
g
found
terminu
rna
strand
case
select
absenc
select
toward
methyl
group
gtp
ligand
would
discrimin
two
function
charrel
et
al
issu
inform
also
sometim
essenti
overcom
limit
protein
remain
reluct
crystal
case
ligand
includ
crystal
addit
exampl
flaviviru
methyltransferas
crystal
major
case
endogen
methyl
cosubstr
coproduct
indic
presenc
ligand
help
stabil
crystal
function
predict
clear
eg
rdrp
number
assay
perform
character
enzym
guid
toward
futur
structur
studi
avail
reason
amount
pure
solubl
protein
also
great
incent
test
possibl
mechan
mani
protein
even
protein
reluct
crystal
eg
first
demonstr
activ
rdrp
arterivirida
famili
beeren
et
al
perhap
greater
activ
section
provid
small
molecul
inhibitor
serv
dual
essenti
purpos
first
may
becom
drug
lead
section
intens
activ
mine
literatur
search
known
inhibitor
could
begin
second
life
newli
avail
crystal
structur
altern
vizier
crystal
structur
provid
first
choic
materi
understand
mode
action
compound
discov
partner
lab
vizierindepend
screen
campaign
part
activ
section
also
dedic
infect
cell
work
connect
structur
data
inde
select
grow
mutant
virus
resist
drug
allow
map
precis
site
action
avail
structur
becom
signific
advantag
drug
design
case
data
mine
identifi
old
drug
led
renew
interest
target
precis
map
achiev
norder
et
al
issu
picornaviru
case
discoveri
drug
candid
preced
highresolut
structur
work
protein
first
crystal
structur
essenti
enzym
certainli
boost
develop
drug
target
type
enzym
presum
helicas
period
vizier
project
achiev
close
collabor
among
scientif
field
cultur
usual
natur
meet
wonder
wit
mutual
scientif
curios
open
new
collabor
action
contribut
build
project
cultur
thu
surpris
initi
structur
genom
project
shift
toward
antivir
drug
develop
effort
latter
repres
undisput
common
ground
project
time
cours
crystal
structur
determin
see
fig
tabl
exceed
origin
object
structur
genom
part
importantli
vast
major
crystal
structur
publish
document
function
assay
fact
deviat
idea
structur
genom
project
simpli
dump
technolog
data
common
unanalys
resourc
largescal
nucleotid
sequenc
would
produc
unannot
sequenc
crystal
structur
undoubtedli
repres
valuabl
inform
may
may
use
antivir
design
futur
often
repres
first
structur
scientif
knowledg
obtain
neglect
viru
famili
infinit
beauti
imagin
natur
protein
architectur
enzym
mechan
last
much
longer
project
gener
enthusiasm
result
perhap
contribut
attract
young
talent
multidisciplinari
virolog
scienc
